

### **Amendments to the Claims**

1. -18. (Cancelled)

19. (Currently Amended) A method for inducing apoptosis in imatinib mesylate refractory cancer cells, the method comprising the steps of contacting the living cells with a imatinib mesylate and suberoylanilide hydroxamic acid wherein the living cells are selected from the group consisting of chronic myelogenous leukemia cells and acute lymphoblastic leukemia cells.

20. (Canceled)

21. (Canceled)

22. (Canceled)

23. (Currently Amended) Method of claim 19 wherein the living cells are exposed to ~~the tyrosine kinase inhibitor~~ imatinib mesylate and ~~the histone deacetylase inhibitor~~ suberoylanilide hydroxamic acid for about 48 hours.

24. (Canceled)

25. (Canceled)

26. (Currently Amended) The method of claim 19 wherein the chronic myelogenous leukemia cells are selected from the group consisting of accelerated-phase chronic myelogenous leukemia cells and blast crisis phase myelogenous leukemia cells.

27. (New) The method of claim 19 wherein the acute lymphoblastic leukemia cells are selected from the group consisting of accelerated-phase acute lymphoblastic leukemia cells and blast crisis phase acute lymphoblastic leukemia cells.